Shinzato Toru, Maeda Kenji
Daiko Medical Engineering Research Institute, Nagoya, Japan.
Contrib Nephrol. 2007;158:169-176. doi: 10.1159/000107247.
Push/pull hemodiafiltration is characterized by alternate filtration and backfiltration, while sterile pyrogen-free dialysate is flowing through a hemodiafilter. During the filtration phase, uremic substances are eliminated not only by diffusive, but also by convective transport. During the backfiltration phase, dialysate is quickly pushed to the blood side (i.e. backfiltration) so as to make up for the excessive reduction in body fluid that has developed during the immediately preceding filtration phase. In the most recently improved version of push/pull hemodiafiltration, the body fluid replacement volume is over 120 liters during a 4- hour treatment. This replacement of a large amount of body fluid may be due to the increased filtration rate in the hemodiafilter resulting from failure of the complete formation of a protein gel layer on the blood side surface. The filtration time in push/pull hemodiafiltration is so short that the also short backfiltration to follow may take over before the protein gel layer is completely formed on the membrane surface. Since the filtration and backfiltration times are much shorter in push/pull hemodiafiltration than the time for blood to pass through the hemodiafilter, it is concentrated and diluted many times (approx. 25 times) before it leaves the hemodiafilter. Therefore, push/pull hemodiafiltration is functionally similar to a predilution hemodiafiltration. The reduction rate of beta-microglobulin was greater by push/pull hemodiafiltration than by hemodialysis, when a high-flux polysulfone hemodiafilter was employed. However, the difference in the reduction rate was rather small between them, because of the improved hemodiafilters, which remove so much beta2-microglobulin only by dialysis. Nevertheless, restless legs syndrome, irritability, insomnia and pruritus were alleviated after switching the treatment modality from hemodialysis to push/pull hemodiafiltration. This may indicate that these symptoms are caused by the accumulation of uremic substances larger than beta2-microglobulin.
推挽式血液透析滤过的特点是在无菌无热原的透析液流经血液透析滤过器时交替进行过滤和回滤。在过滤阶段,尿毒症物质不仅通过扩散,还通过对流运输被清除。在回滤阶段,透析液迅速被推至血液侧(即回滤),以弥补在前一过滤阶段出现的体液过度减少。在推挽式血液透析滤过的最新改进版本中,4小时治疗期间的体液置换量超过120升。大量体液的这种置换可能是由于血液侧表面未能完全形成蛋白质凝胶层导致血液透析滤过器的过滤速率增加。推挽式血液透析滤过的过滤时间非常短,以至于随后同样短暂的回滤可能在膜表面蛋白质凝胶层完全形成之前就开始了。由于推挽式血液透析滤过中的过滤和回滤时间比血液流经血液透析滤过器的时间短得多,所以在血液离开血液透析滤过器之前会被浓缩和稀释很多次(约25次)。因此,推挽式血液透析滤过在功能上类似于前稀释血液透析滤过。当使用高通量聚砜血液透析滤过器时,推挽式血液透析滤过对β2-微球蛋白的清除率比血液透析更高。然而,由于改进后的血液透析滤过器仅通过透析就能清除大量的β2-微球蛋白,它们之间的清除率差异相当小。尽管如此,将治疗方式从血液透析切换为推挽式血液透析滤过后,不安腿综合征、易怒、失眠和瘙痒症状得到了缓解。这可能表明这些症状是由大于β2-微球蛋白的尿毒症物质积累引起的。